269 DNA and RNA alterations associated with colorectal peritoneal metastases: A systematic review ed guideline for reporting systematic reviews. Syst. Rev. 2021, 10, 89. https://doi.org/10.1186/ s13643-021-01626-4. [19] Ouzzani, M.; Hammady, H.; Fedorowicz, Z.; Elmagarmid, A. Rayyan—A web and mobile app for systematic reviews. Syst. Rev. 2016, 5, 210. https://doi.org/10.1186/s13643-016-0384-4. [20] Astrosini, C.; Roeefzaad, C.; Dai, Y.Y.; Dieckgraefe, B.K.; Jöns, T.; Kemmner, W. REG1A expression is a prognostic marker in colorectal cancer and associated with peritoneal carcinomatosis. Int. J. Cancer 2008, 123, 409–413. https://doi. org/10.1002/ijc.23466. [21] Bruzzi, M.; Auclin, E.; Lo Dico, R.; Voron, T.; Karoui, M.; Espin, E.; Cianchi, F.; Weitz, J.; Buggenhout, A.; Malafosse, R.; et al. Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: A Post Hoc Analysis of the PETACC-8 Trial. Ann. Surg. Oncol. 2019, 26, 3561–3567. https://doi.org/10.1245/ s10434-019-07513-6. [22] Cheng, H.H.; Lin, J.K.; Chen, W.S.; Jiang, J.K.; Yang, S.H.; Chang, S.C. Clinical significance of the BRAFV600E mutation in Asian patients with colorectal cancer. Int. J. Color. Dis. 2018, 33, 1173–1181. https://doi.org/10.1007/s00384018-3095-6. [23] He, K.; Wang, Y.; Zhong, Y.; Pan, X.; Si, L.; Lu, J. KRAS Codon 12 Mutation is Associated with More Aggressive Invasiveness in Synchronous Metastatic Colorectal Cancer (mCRC): Retrospective Research. Onco Targets Ther. 2020, 13, 12601–12613. https://doi.org/10.2147/ott. S279312. [24] Heublein, S.; Albertsmeier, M.; Pfeifer, D.; Loehrs, L.; Bazhin, A.V.; Kirchner, T.; Werner, J.; Neumann, J.; Angele, M.K. Association of differential miRNA expression with hepatic vs. peritoneal metastatic spread in colorectal cancer. BMC Cancer 2018, 18, 201. https://doi. org/10.1186/s12885-018-4043-0. [25] Jacob, S.; Bösch, F.; Schoenberg, M.B.; Pretzsch, E.; Lampert, C.; Haoyu, R.; Renz, B.W.; Michl, M.; Kumbrink, J.; Kirchner, T.; et al. Expression of CIB1 correlates with colorectal liver metastases but not with peritoneal carcinomatosis. BMC Cancer 2021, 21, 1243. https://doi.org/10.1186/ s12885-021-08927-w. [26] Jacob, S.; Jurinovic, V.; Lampert, C.; Pretzsch, E.; Kumbrink, J.; Neumann, J.; Haoyu, R.; Renz, B.W.; Kirchner, T.; Guba, M.O.; et al. The association of immunosurveillance and distant metastases in colorectal cancer. J. Cancer Res. Clin. Oncol. 2021, 147, 3333–3341. https://doi.org/10.1007/ s00432-021-03753-w. [27] Kawazoe, A.; Shitara, K.; Fukuoka, S.; Kuboki, Y.; Bando, H.; Okamoto, W.; Kojima, T.; Fuse, N.; Yamanaka, T.; Doi, T.; et al. A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. BMC Cancer 2015, 15, 258. https://doi.org/10.1186/s12885-015-1276-z. [28] Lan, Y.T.; Jen-Kou, L.; Lin, C.H.; Yang, S.H.; Lin, C.C.; Wang, H.S.; Chen, W.S.; Lin, T.C.; Jiang, J.K.; Chang, S.C. Mutations in the RAS and PI3K pathways are associated with metastatic location in colorectal cancers. J. Surg. Oncol. 2015, 111, 905–910. https://doi.org/10.1002/jso.23895. [29] Lan, Y.T.; Chang, S.C.; Lin, P.C.; Lin, C.H.; Liang, W.Y.; Chen, W.S.; Jiang, J.K.; Yang, S.H.; Lin, J.K. High concordance of mutation patterns in 10 common mutated genes between tumor tissue and cell-free DNA in metastatic colorectal cancer. Am. J. Cancer Res. 2021, 11, 2228–2237. [30] Lee, J.H.; Ahn, B.K.; Baik, S.S.; Lee, K.H. Comprehensive Analysis of Somatic Mutations in Colorectal Cancer With Peritoneal Metastasis. Vivo 2019, 33, 447–452. https://doi.org/10.21873/ invivo.11493. [31] Nagahara, M.; Nishida, N.; Iwatsuki, M.; Ishimaru, S.; Mimori, K.; Tanaka, F.; Nakagawa, T.; Sato, T.; Sugihara, K.; Hoon, D.S.; et al. Kinesin 18A expression: Clinical relevance to colorectal cancer progression. Int. J. Cancer 2011, 129, 2543–2552. https://doi.org/10.1002/ijc.25916. [32] Sakuraba, K.; Yasuda, T.; Sakata, M.; Kitamura, Y.H.; Shirahata, A.; Goto, T.; Mizukami, H.; Saito, M.; Ishibashi, K.; Kigawa, G.; et al. Down-regulation of Tip60 gene as a potential marker for the malignancy of colorectal cancer. Anticancer Res. 2009, 29, 3953–3955. [33] Sasaki, Y.; Hamaguchi, T.; Yamada, Y.; Takahashi, N.; Shoji, H.; Honma, Y.; Iwasa, S.; Okita, N.; Takashima, A.; Kato, K.; et al. Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis. Asian Pac. J. Cancer Prev. 2016, 17, 539–543. https://doi. org/10.7314/apjcp.2016.17.2.539. [34] Sayagués, J.M.; Del Carmen, S.; Del Mar Abad, M.; Corchete, L.A.; Bengoechea, O.; Anduaga, M.F.; Baldeón, M.J.; Cruz, J.J.; Alcazar, J.A.; Angoso, M.; et al. Combined assessment of the TNM stage and BRAF mutational status at diagnosis in sporadic colorectal cancer patients. Oncotarget 2018, 9, 24081–24096. https://doi. org/10.18632/oncotarget.25300. [35] Shelygin, Y.A.; Pospekhova, N.I.; Shubin, V.P.; Kashnikov, V.N.; Frolov, S.A.; Sushkov, O.I.; 11
RkJQdWJsaXNoZXIy MTk4NDMw